DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aredia (Pamidronate Disodium) - Published Studies

 
 



Aredia Related Published Studies

Well-designed clinical trials related to Aredia (Pamidronate)

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. [2011.05]

Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant. [2011.01]

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. [2010.10]

Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. [2009.05]

Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. [2009.02]

Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous Doxorubicin for canine appendicular osteosarcoma bone pain. [2009.01]

Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. [2008.09.15]

Two doses of pamidronate in infants with osteogenesis imperfecta. [2008.05]

Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. [2008]

Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. [2006.11]

Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. [2006.09]

Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. [2006.01]

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. [2006.01]

Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. [2006]

Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. [2006]

Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. [2005.11]

Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. [2005.07]

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. [2005.06]

Muscle atrophy and bone loss after 90 days' bed rest and the effects of flywheel resistive exercise and pamidronate: results from the LTBR study. [2005.06]

Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. [2005.06]

The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study. [2005.06]

Effect of pamidronate administration on bone in patients with acute spinal cord injury. [2005.05]

[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis] [2005.03]

Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. [2005.01]

Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. [2005]

Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy. [2004.12]

[Pamidronate in treatment of pain caused by bone metastasis] [2004.11]

Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. [2004.11]

Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. [2004.10]

Efficacy of pamidronate in complex regional pain syndrome type I. [2004.09]

Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy. [2004.04.15]

A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. [2004.04]

Home care versus hospital care in patients with multiple myeloma treated with pamidronate. [2004.03]

Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. [2004.02]

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. [2004.01.01]

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. [2003.12.01]

A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. [2003.12]

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. [2003.10.15]

Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. [2003.10]

Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty. [2003.10]

Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. [2003.09]

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. [2003.08]

Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. [2003.07]

Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. [2003.06]

A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. [2003.04]

Response to alendronate in osteoporotic women previously treated with pamidronate. [2003.02.25]

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. [2003.01]

Bone density changes in Paget's disease 2 years after iv pamidronate: profound, sustained increases in pagetic bone with severity-related loss in forearm nonpagetic cortical bone. [2003.01]

Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. [2002.12]

Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). [2002.11]

Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. [2002.07]

Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study. [2002.06]

Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. [2002.06]

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. [2002.03]

Comparable bioavailability of two esophago-gastric protective formulations containing pamidronate. A cross-over trial in healthy young adults. [2002]

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. [2001.10]

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. [2001.09.27]

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. [2001.09.15]

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. [2001.09]

The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. [2001.06]

Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. [2001.04]

Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. [2001.03]

Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. [2001.01]

Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. [2000.11]

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. [2000.11]

Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. [2000.09]

Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. [2000.08]

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. [2000.03.01]

Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. [2000.03]

Pamidronate therapy as prevention of bone loss following renal transplantation1. [2000.02]

Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. [2000]

Changes in calcium homoeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively. [1999.08]

Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. [1999.07]

Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. [1999.07]

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. [1999.03]

Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium. [1999.02]

Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? [1999.01]

Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. [1999.01]

Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. [1999]

Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. [1998.08]

Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. [1998.07]

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. [1998.06]

A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. [1998.05]

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. [1998.05]

Different doses of pamidronate in patients with painful osteolytic bone metastases. [1998.03]

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. [1998.02]

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. [1997.12]

High dose pamidronate: clinical and biochemical effects in metastatic bone disease. [1997.10.15]

Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. [1997.10]

Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. [1997.01]

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. [1996.12.12]

Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. [1996.10]

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. [1996.09]

Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? [1996.03]

Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. [1996.03]

Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. [1996.02.22]

Role of oral pamidronate in preventing bone loss in postmenopausal women. [1996]

Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. [1995.11]

A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. [1995.11]

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. [1994.12.01]

Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. [1994.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012